Vitamin E Deficiency and Excess: Dietary Sources, Antioxidant Mechanisms, and Toxicity Risks

Vitamin E preferentially intercalates into phospholipid bilayers to safeguard polyunsaturated fatty acids (PUFAs):

• Primary Nutritional Vectors: Cold-pressed unrefined vegetable oils (wheat germ oil serving as the densest natural reservoir with >150 mg/100 g, alongside sunflower and hazelnut oils), almonds, sunflower seeds, and avocados.
• Free Radical Scavenging Dynamics: The phenolic hydroxyl group on the chromanol ring donates a hydrogen atom to lipid peroxyl radicals (LOO•), generating stable lipid hydroperoxides and interrupting the autoxidative destruction of cellular membranes.
• The Ascorbate-Glutathione-Selenium Cycle: The resulting tocopheroxyl radical is systematically regenerated to bioactive alpha-tocopherol by cytosolic ascorbic acid and reduced glutathione. Concurrently, selenium-dependent glutathione peroxidase (GPx) metabolizes toxic lipid peroxides into harmless alcohols.

Nutritional deprivation alone is exceptionally rare; clinically significant deficiency is almost uniformly secondary to severe lipid malabsorption:

• Pathophysiological Etiologies: Cystic fibrosis (pancreatic exocrine insufficiency), cholestatic liver disease, celiac sprue, short bowel syndrome, abetalipoproteinemia, and genetic ataxia with vitamin E deficiency (AVED, caused by mutations in the alpha-tocopherol transfer protein gene).
• Spinocerebellar and Neuromuscular Degeneration: Progressive demyelination and axonal spheroids in the posterior columns of the spinal cord. Manifests as sensory ataxia (gait impairment), hyporeflexia, and profound loss of vibratory and position sensation (proprioception).
• Peripheral Neuropathy and Retinal Dystrophy: Progressive skeletal myopathy, dysarthria, ophthalmoplegia, and pigmented retinopathy culminating in visual field deficits.
• Hemolytic Anemia in Preterm Neonates: Premature infants exhibit heightened erythrocyte membrane fragility due to deficient tocopherol shielding against atmospheric hyperoxia.

The presumption of complete benignity is contradicted by clinical evidence surrounding high-dose supplement misuse:

• Tolerable Upper Intake Levels (UL): EFSA caps daily adult exposure at 300 mg of alpha-tocopherol (approx. 450 IU), whereas the US Institute of Medicine establishes 1,000 mg/day (1,500 IU) as the physiological limit.
• Antagonism with Vitamin K Coagulation Cascades: Excessive concentrations of alpha-tocopherol displace phylloquinone/menaquinone, competitively inhibiting vitamin K-dependent gamma-glutamyl carboxylase in hepatocytes. This halts activation of clotting factors II, VII, IX, and X, predisposing to spontaneous hemorrhage.
• Pharmacological Contraindications: Strict prohibition against megadosing applies to patients receiving anticoagulant (warfarin, DOACs) or antiplatelet therapy due to compounding hemorrhagic stroke risk.
• The Pro-Oxidant Paradox: Large-scale trials (e.g., SELECT and HOPE) demonstrated that pharmacologic monotherapy fails to confer cardiovascular protection and may paradoxically enhance oxidative stress or heart failure incidence in compromised individuals.